Recurrent chromosomal abnormalities present in malignant cells often define subentities with unique biological and clinical features. The molecular identification of genes involved in genetic alterations has led to the characterization of fusion genes with neoplastic properties. However, for many nonrandom translocations including the dic(9;12)(p11-13;p11-12), the molecular equivalent has not as yet been identified. The dicentric translocation dic(9;12) is a recurrent chromosome abnormality that accounts for close to 1% of childhood acute lymphoblastic leukemia (ALL). This specific alteration occurs almost exclusively in B-progenitor ALL, and unlike many other nonrandom translocations, is associated with an excellent prognosis. In this work, we provide strong evidence that the PAX5/ETV6 fusion transcript defines the clinical and biological entity that is associated with the presence of a dic(9;12) chromosome. As the PAX5 and ETV6 genes are localized at 9p13 and 12p13, respectively, the cytogenetic description of the dic(9;12)-PAX5/ETV6 rearrangement should be refined to dic(9;12)(p13;p13).
Introduction
The dicentric translocation dic(9;12)(p11-13;p11-12) was first described by Carroll et al. 1 in 1987 as recurrent chromosome abnormality in childhood acute lymphoblastic leukemia (ALL) with an incidence of slightly less than 1%. Although in ALL the dic(9;12) chromosome defines a well-known cytogenetic and clinical entity, rare cases have also been found in other Blineage malignancies, such as lymphoid (CD10+) blast crises of chronic myelocytic leukemia (CML) or in T-cell lymphoblastic lymphoma. 2, 3 The vast majority of leukemias with dic(9;12) is associated with a B-progenitor cell phenotype and belongs to the FAB L1 morphologic subtype. The blast cells express HLA-DR, CD10, CD19, CD24, and frequently also CD20 or CD22. 2, 3 Most importantly, children with dic(9;12) fare extremely well, regardless of the specific type of therapy or the presence of one or more established poor risk features. 2 The clinical relevance and a certain difficulty in resolving the dic(9;12) by conventional cytogenetics underscore the importance of molecular or FISH testing to identify this lesion. However, the underlying molecular genetic alteration of the dic(9;12) chromosome has not as yet been identified and therefore no other assay that would adequately supplement chromosome analysis was available. In this study, we report two cases with dic(9;12) and a PAX5/ETV6 fusion transcript. Our data provide compelling evidence that the PAX5/ETV6 fusion, which was previously described only in a single case with a t(9;12), in fact represents the molecular equivalent of the clinical and biological entity that is defined by the presence of a dic(9;12) chromosome.
Study design

Patients
Case 1: In January 2002, a 12-year old girl was diagnosed with ALL L1 according to the French-American-British (FAB) classification. The white blood cell (WBC) count was 15.8 Â 10 9 /l with a 92% blast cell infiltration of the bone marrow. Immunophenotyping of the blast cells revealed expression of CD10, CD19, CD20, CD34, cyCD22, CD79a, TdT, and HLA-DR. The patient was treated according to the ALL-BFM2000 protocol. Conventional G-banding analysis identified a t(9;12)(p12;p13) in most of the metaphases. However, following FISH analysis (see Results and discussion) the complete karyotype was refined and described according to the ISCN nomenclature: 4 45,XX,dic(9;12)(p13;p13) [2] /44, XX,idem,-1der(2)t(2;7)(p11?;q11?),À7 [11] /46,XX [2] .
Case 2: A 13.4-year-old boy was diagnosed with ALL L1 in 1994. The WBC count was 9.2 x 10 9 /l and the bone marrow had a 95% blast cell infiltration. The blast cells were CD10, CD19, CD22, CD34, and HLA-DR positive. The patient was treated according to the ALL-BFM86 protocol and remains in continuous remission. Cytogenetic analysis revealed the following karyotype: 45,XY,dic(9;12)(p11-12;p11-12)[2]/46,XY, idem,+8 [2] /46,XY [6] .
Cytogenetic and FISH analysis
Cytogenetic analysis was performed according to standard techniques. FISH analysis was performed using PAX5-and ETV6-specific probes. The PAX5 probes were two cosmids (kindly provided by M Busslinger, IMP, Vienna, Austria), coshPAX5-1 and cos-hPAX5-3 containing exons 2-5 and exons 9 and 10 of the PAX5 gene, respectively. 5 The ETV6-specific probes were cosmids 179A6 (exon 1), 50F4 (exon 2), and 148B6 (exon 8) (kindly provided by P Marynen, Center for Human Genetics, University of Leuven, Leuven, Belgium). 6 In order to confirm the dicentric nature of the dic(9;12) centromere-specific probes D9Z5 and D12Z1 were used.
RT-PCR analysis
RT-PCR with PAX5-and ETV6-specific primers was performed on patient cDNA using sense primer PAX5ex3-F1 (5 0 -CCAT GTTTGCCTGGGAGATCAG-3 0 ) and antisense primer ETV6ex3-R1 (5 0 -CCTCTTTGGTCAGCAGCAGGAG-3 0 ). After initial denaturation for 14 min at 951C cDNA amplification was carried out for 35 cycles using HotStartTaq (Qiagen GmbH, Germany) and 30 s 951C, 30 s 661C, and 30 s 721C as cycling conditions. Amplification of normal PAX5 was achieved with primers PAX5ex1A-F1 (5 0 -CCGACTCCTCGGACCAGC-3 0 ) and PAX5-ex1B-F1 (5 0 -CACGACCCGTTTGCATCC-3 0 ) localized in the alternative first exons 1A and 1B, respectively, and PAX5ex5-R1 (5 0 -GCCGAATCCGTGCTCACC-3 0 ). Cycling conditions were as outlined above except for annealing at 641C. Direct sequencing of RT-PCR products was done by MWG-Biotech (Ebersberg, Germany).
Results and discussion
Cytogenetic analysis of two ALL patients initially revealed a t(9;12)(p12;p13) and a dic(9;12)(p11-
0 -end of the gene was deleted (Figure 1a ). To the best of our knowledge, 18 different ETV6 fusion partner genes have been described and four of them are localized on chromosome 9: 9p13 (PAX5), 7 9p24 (JAK2), 8 9q22 (SYK), 9 and 9q34 (ABL). 10 According to the breakpoints determined by cytogenetic analysis, in our specific cases PAX5 was the most likely ETV6 fusion partner candidate gene. This notion was substantiated by FISH experiments using PAX5 gene-specific probes. Hybridization with cosmid clones specific for the 5 0 -and the 3 0 -end of PAX5 resulted in an opposite FISH pattern to that observed with the ETV6 probes. In case of PAX5, the 5 0 -end of the gene was localized on the dic(9;12) chromosome, whereas the 3 0 -end of the gene was deleted (Figure 1b) . On the molecular level, the presence of a PAX5/ETV6 fusion transcript was verified by fusion gene-specific RT-PCRs (Figure 2a) . In both cases, sequencing of the RT-PCR products revealed the same fusion transcript that has been previously described, namely a fusion of PAX5 exon 4 to exon 3 of the ETV6 gene. 7 Further RT-PCR analyses revealed the presence of both alternative fusion transcripts between PAX5 exon 1A and 1B and ETV6 (Figure 2b and c) . Owing to the loss of the FISH signals corresponding to the ETV6/PAX5 fusion, the presence of the reciprocal chimeric transcript was not further investigated. The PAX5/ETV6 chimeric transcript results in the fusion of the paired box domain (PRD) of the transcription factor PAX5 to the helix-loop-helix and ETS-binding domains of ETV6. Interestingly, the putative chimeric protein contains the DNA-binding domains of both fusion partners, namely the PRD and the ETSdomain. Although the function of the PAX5/ETV6 fusion protein remains elusive, it has been speculated that it might act as an aberrant transcription factor, which could affect both the PAX5 and ETV6 pathways of transcription modulation.
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PAX5 encodes the transcription factor B-cell-specific activator protein (BSAP), which is essential for the generation as well as the maintenance of B-lineage-committed cells. 11, 12 Expression of the CD19 gene is highly sensitive to the dosage of BSAP and strictly dependent on full-length BSAP. 13 Of note, CD19 expression of the blast cells did not differ from a series of other phenotype-matched B-cell precursor ALLs (data not shown), suggesting expression of normal PAX5 from the second allele and no impairment of CD19 expression by the PAX5/ETV6 putative fusion protein. Indeed, according to the FISH data the second allele of PAX5 was retained and RT-PCR for normal PAX5 verified expression of both wild-type PAX5A and PAX5B splice variants (Figure 2d and e) . 5 In most cases, the presence of a specific fusion gene can be linked to a particular chromosome alteration. The only welldefined cytogenetic and clinical entity involving the distinct Figure 1 FISH analysis of case 1. (a) FISH using ETV6 exonspecific probes. The ETV6 3 0 -end represented by the exon 8-specific cosmid 148B6 (green signals) remained on the dic(9;12) chromosome, and the cosmid clones 179A6 and 50F4, specific for exons 1 and 2, respectively (red signals), and thus covering the ETV6 5 0 -end were deleted. (b) FISH on the same metaphase as in (a) using PAX5 exonspecific probes. cos-hPAX5-1 containing exons 2-5 (red signals) was retained, whereas cos-hPAX5-3 covering exons 9 and 10 (green signals) was deleted. (c) FISH using centromere-specific probes for chromosomes 9 (red signals) and 12 (green signals); the arrow depicts the dic(9;12) chromosome.
PAX5/ETV6 fusion is associated with dic(9;12)(p13;p13) S Strehl et al breakpoints observed in the two cases with the PAX5/ETV6 fusion is the dic(9;12)(p11-13;p11-12). 2, 3 Such dicentrics, in particular the exact breakpoints, may be difficult to detect by conventional banding techniques and thus, FISH analysis was performed. In both samples, hybridization with centomerespecific probes for chromosomes 9 and 12 clearly detected a dic(9;12) chromosome (Figure 1c ). PAX5 and ETV6 are localized at 9p13 and 12p13, respectively, and therefore the cytogenetic description of the dic(9;12)-PAX5/ETV6 rearrangement should be refined to dic(9;12)(p13;p13). So far, only one single case with a PAX5/ETV6 fusion has been analyzed and the karyotype was described as: 43,XY,-4,-9,der(12)t(9;12)(q11;p13),-19. 7 Although the chromosomal breakpoints did not exactly coincide with those of the dic(9;12), the karyotype is highly suggestive for such an aberration.
The data presented provide compelling evidence that the dic(9;12) which has been described as nonrandom chromosome abnormality that predominantly occurs in pre-B hematopoietic malignancies is associated with fusion of the PAX5 and ETV6 genes. Linking this specific molecular genetic alteration to the dic(9;12) cytogenetic entity provides us with the necessary knowledge to perform molecular and FISH testing to identify this genetic lesion and to adequately supplement cytogenetic analysis. Refined evaluation of larger series of patients will allow to determine the overall incidence of the dic(9;12)-PAX5/ ETV6 rearrangement and to verify if at the molecular level the dic(9;12) chromosomes found in ALL differ from those observed in CML or T-cell disease. 2 Accurate detection of the PAX5/ETV6 genetic alteration at diagnosis will significantly improve risk evaluation and therapy stratification.
